目次

TABLE OF CONTENTS

1 INTRODUCTION (Page No. - 33)
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
FIGURE 1 INCLUSIONS & EXCLUSIONS
1.2.1 MARKETS COVERED
FIGURE 2 MOLECULAR DIAGNOSTICS MARKET
1.2.2 YEARS CONSIDERED FOR THE STUDY
1.3 CURRENCY
1.4 LIMITATIONS
1.5 STAKEHOLDERS
1.6 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY (Page No. - 38)
2.1 RESEARCH DATA
2.2 RESEARCH APPROACH
FIGURE 3 MOLECULAR DIAGNOSTICS MARKET: RESEARCH DESIGN METHODOLOGY
2.2.1 SECONDARY DATA
2.2.1.1 Key data from secondary sources
2.2.2 PRIMARY DATA
2.2.2.1 Key data from primary sources
2.2.2.2 Key industry insights
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
2.3 MARKET SIZE ESTIMATION
2.3.1 BOTTOM-UP APPROACH
FIGURE 5 MOLECULAR DIAGNOSTICS MARKET: BOTTOM-UP APPROACH
FIGURE 6 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
2.3.2 TOP-DOWN APPROACH
FIGURE 7 MOLECULAR DIAGNOSTICS MARKET: TOP-DOWN APPROACH
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
FIGURE 8 DATA TRIANGULATION METHODOLOGY
2.5 ASSUMPTIONS FOR THE STUDY
2.6 COVID-19 HEALTH ASSESSMENT
2.7 COVID-19 ECONOMIC ASSESSMENT
2.8 ASSESSMENT OF THE IMPACT OF COVID-19 ON THE ECONOMIC SCENARIO
FIGURE 9 CRITERIA IMPACTING THE GLOBAL ECONOMY
FIGURE 10 RECOVERY SCENARIO OF THE GLOBAL ECONOMY
2.9 ASSESSMENT OF THE IMPACT OF COVID-19 ON THE ECONOMIC SCENARIO IN THE MOLECULAR DIAGNOSTICS MARKET

3 EXECUTIVE SUMMARY (Page No. - 52)
FIGURE 11 MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021 VS. 2026 (USD MILLION)
FIGURE 12 MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2021 VS. 2026 (USD MILLION)
FIGURE 13 MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021 VS. 2026 (USD MILLION)
FIGURE 14 MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021 VS. 2026 (USD MILLION)
FIGURE 15 MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021 VS. 2026 (USD MILLION)
FIGURE 16 MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2021 VS. 2026 (USD MILLION)

4 PREMIUM INSIGHTS (Page No. - 56)
4.1 MOLECULAR DIAGNOSTICS MARKET OVERVIEW
FIGURE 17 THE RISING ADOPTION OF POC DIAGNOSTICS IS EXPECTED TO SUPPORT MARKET GROWTH DURING THE FORECAST PERIOD
4.2 MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021 VS. 2026 (USD MILLION)
FIGURE 18 THE REAGENTS & KITS SEGMENT IS EXPECTED TO COMMAND THE LARGEST SHARE OF THE MARKET, BY PRODUCT & SERVICE, IN 2021
4.3 MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021 VS. 2026 (USD MILLION)
FIGURE 19 THE PCR SEGMENT IS EXPECTED TO HOLD THE LARGEST SHARE OF THE MARKET DURING THE FORECAST PERIOD
4.4 MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021 VS. 2026
FIGURE 20 THE DIAGNOSTIC LABORATORIES SEGMENT IS EXPECTED TO HOLD THE LARGEST SHARE OF THE END USER MARKET DURING THE FORECAST PERIOD

5 MARKET OVERVIEW (Page No. - 59)
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 21 MOLECULAR DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.2.1 DRIVERS
5.2.1.1 The increasing prevalence of infectious diseases and cancer
5.2.1.2 Rising focus on R&D and funding in molecular diagnostics
5.2.1.3 Increasing awareness for early disease diagnosis in developing countries
5.2.1.4 Rising technological advancements in molecular diagnostics
5.2.1.5 Increasing use of PoC diagnostic tests
5.2.2 RESTRAINT
5.2.2.1 Unfavorable reimbursement scenario
5.2.2.2 The high cost of instruments
5.2.3 OPPORTUNITIES
5.2.3.1 The growing significance of companion diagnostics
5.2.3.2 Growth opportunities in emerging countries
5.2.4 CHALLENGES
5.2.4.1 Changing regulatory landscape
5.2.4.2 Operational barriers
5.2.4.3 The introduction of alternative technologies
5.2.5 COVID 19 IMPACT ANALYSIS
5.3 PRICING ANALYSIS
TABLE 1 PRICING ANALYSIS OF MOLECULAR DIAGNOSTIC PRODUCTS (2021)
5.4 PATENT ANALYSIS
5.5 VALUE CHAIN ANALYSIS
FIGURE 22 VALUE CHAIN ANALYSIS OF THE MOLECULAR DIAGNOSTICS MARKET
5.6 SUPPLY CHAIN ANALYSIS
FIGURE 23 SUPPLY CHAIN ANALYSIS
5.7 ECOSYSTEM ANALYSIS
5.8 PORTER’S FIVE FORCES ANALYSIS
FIGURE 24 PORTER’S FIVE FORCES ANALYSIS
5.8.1 THREAT FROM NEW ENTRANTS
5.8.2 THREAT FROM SUBSTITUTES
5.8.3 BARGAINING POWER OF BUYERS
5.8.4 BARGAINING POWER OF SUPPLIERS
5.8.5 COMPETITIVE RIVALRY AMONG EXISTING PLAYERS
5.9 PESTLE ANALYSIS
5.10 REGULATORY LANDSCAPE
5.10.1 NORTH AMERICA
5.10.1.1 US
5.10.1.2 Canada
5.10.2 EUROPE
5.10.3 ASIA PACIFIC
5.10.3.1 China
5.10.3.2 Japan
5.10.3.3 India
5.10.4 LATIN AMERICA
5.10.4.1 Brazil
5.10.4.2 Mexico
5.10.5 MIDDLE EAST
5.10.6 AFRICA
5.11 TRADE ANALYSIS
5.11.1 TRADE ANALYSIS FOR DIAGNOSTIC AND LABORATORY REAGENTS
5.11.1.1 Import data for diagnostic and laboratory reagents, by country, 2016─2020 (USD Million)
5.11.1.2 Import data for diagnostic and laboratory reagents, by country, 2016─2020 (Tons)
5.12 TECHNOLOGY ANALYSIS

6 MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE (Page No. - 77)
6.1 INTRODUCTION
TABLE 2 MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION)
6.2 REAGENTS & KITS
6.2.1 THE RECURRENT PURCHASE OF REAGENTS & KITS IS A MAJOR FACTOR DRIVING MARKET GROWTH
TABLE 3 REAGENTS & KITS MARKET, BY REGION, 2019-2026 (USD MILLION)
6.3 INSTRUMENTS
TABLE 4 INSTRUMENTS MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 5 INSTRUMENTS MARKET, BY REGION, 2019-2026 (USD MILLION)
6.3.1 TABLETOP INSTRUMENTS
6.3.1.1 The outbreak of COVID-19 and rising incidences of cancer drives the growth of this segment
TABLE 6 TABLETOP INSTRUMENTS MARKET, BY REGION, 2019-2026 (USD MILLION)
6.3.2 PORTABLE & POC INSTRUMENTS
6.3.2.1 The increasing adoption of PoC technologies drives the growth of this segment
TABLE 7 PORTABLE & POC INSTRUMENTS MARKET, BY REGION, 2019-2026 (USD MILLION)
6.4 SERVICES & SOFTWARE
6.4.1 THE GROWING UPTAKE OF ADVANCED INSTRUMENTS IN THE MOLECULAR DIAGNOSTICS MARKET DRIVES SEGMENT GROWTH
TABLE 8 SERVICES & SOFTWARE MARKET, BY REGION, 2019-2026 (USD MILLION)

7 MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY (Page No. - 84)
7.1 INTRODUCTION
TABLE 9 MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
7.2 POLYMERASE CHAIN REACTION (PCR)
7.2.1 THE GROWING USE OF PCR IN PROTEOMICS AND GENOMICS IS A MAJOR GROWTH DRIVER FOR THIS SEGMENT
TABLE 10 PCR TECHNOLOGY MARKET, BY REGION, 2019-2026 (USD MILLION)
7.3 ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY (INAAT)
7.3.1 THE COST-BENEFITS OF THIS TECHNOLOGY IS A KEY FACTOR DRIVING THE MARKET GROWTH
TABLE 11 INAAT TECHNOLOGY MARKET, BY REGION, 2019-2026 (USD MILLION)
7.4 DNA SEQUENCING & NEXT-GENERATION SEQUENCING
7.4.1 INCREASING USE OF NGS IN THE DIAGNOSIS OF CANCER IS A GROWTH DRIVER FOR THIS SEGMENT
TABLE 12 DNA SEQUENCING & NGS TECHNOLOGY MARKET, BY REGION, 2019-2026 (USD MILLION)
7.5 IN SITU HYBRIDIZATION (ISH)
7.5.1 THE RISING PREVALENCE OF CANCER AND GENETIC DISORDERS IS A KEY FACTOR DRIVING SEGMENT GROWTH
TABLE 13 ISH TECHNOLOGY MARKET, BY REGION, 2019-2026 (USD MILLION)
7.6 DNA MICROARRAY
7.6.1 THE INTRODUCTION OF DNA MICROARRAY HAS ACCELERATED GENE EXPRESSION AND DISEASE DIAGNOSIS
TABLE 14 DNA MICROARRAY TECHNOLOGY MARKET, BY REGION, 2019-2026 (USD MILLION)
7.7 OTHER TECHNOLOGIES
TABLE 15 OTHER TECHNOLOGIES MARKET, BY REGION, 2019-2026 (USD MILLION)

8 MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION (Page No. - 92)
8.1 INTRODUCTION
TABLE 16 MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
8.2 INFECTIOUS DISEASE DIAGNOSTICS
TABLE 17 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY REGION, 2019-2026 (USD MILLION)
TABLE 18 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE, 2019-2026 (USD MILLION)
8.2.1 COVID-19
8.2.1.1 The outbreak of the pandemic is a key factor driving market growth
TABLE 19 COVID-19 DIAGNOSTICS MARKET, BY REGION, 2019-2026 (USD MILLION)
TABLE 20 COVID-19 DIAGNOSTICS MARKET, BY REGION, 2019-2026 (MILLION TESTS)
8.2.2 HEPATITIS
8.2.2.1 The global prevalence of hepatitis is a key factor driving market growth
TABLE 21 HEPATITIS DIAGNOSTICS MARKET, BY REGION, 2019-2026 (USD MILLION)
TABLE 22 HEPATITIS DIAGNOSTICS MARKET, BY REGION, 2019-2026 (MILLION ASSAYS)
8.2.3 CT/NG
8.2.3.1 CT/NG infections are the most commonly prevalent STDs; key factor driving the market growth
TABLE 23 CT/NG DIAGNOSTICS MARKET, BY REGION, 2019-2026 (USD MILLION)
TABLE 24 CT/NG DIAGNOSTICS MARKET, BY REGION, 2019-2026 (MILLION TESTS)
8.2.4 HIV
8.2.4.1 The increasing number of blood transfusions & donations will drive the market growth for this segment
TABLE 25 HIV DIAGNOSTICS MARKET, BY REGION, 2019-2026 (USD MILLION)
TABLE 26 HIV DIAGNOSTICS MARKET, BY REGION, 2019-2026 (MILLION TESTS)
8.2.5 HAI
8.2.5.1 The rising burden of MRSA infections is a key factor driving the market growth for this segment
TABLE 27 HAI DIAGNOSTICS MARKET, BY REGION, 2019-2026 (USD MILLION)
TABLE 28 HAI DIAGNOSTICS MARKET, BY REGION, 2019-2026 (MILLION TESTS)
8.2.6 HPV
8.2.6.1 Technological advancements such as rapid HPV diagnostics to drive the market growth for this segment
TABLE 29 HPV DIAGNOSTICS MARKET, BY REGION, 2019-2026 (USD MILLION)
TABLE 30 HPV DIAGNOSTICS MARKET, BY REGION, 2019-2026 (MILLION TESTS)
8.2.7 TUBERCULOSIS
8.2.7.1 The increasing burden of TB globally to drive the market growth of this segment
TABLE 31 TUBERCULOSIS DIAGNOSTICS MARKET, BY REGION, 2019-2026 (USD MILLION)
TABLE 32 TUBERCULOSIS DIAGNOSTICS MARKET, BY REGION, 2019-2026 (MILLION TESTS)
8.2.8 INFLUENZA
8.2.8.1 The rising focus on containing the spread of influenza drives the market growth for this segment
TABLE 33 INFLUENZA DIAGNOSTICS MARKET, BY REGION, 2019-2026 (USD MILLION)
TABLE 34 INFLUENZA DIAGNOSTICS MARKET, BY REGION, 2019-2026 (MILLION TESTS)
8.2.9 OTHER INFECTIOUS DISEASES
TABLE 35 OTHER INFECTIOUS DISEASES MARKET, BY REGION, 2019-2026 (USD MILLION)
8.3 ONCOLOGY TESTING
TABLE 36 ONCOLOGY TESTING MARKET, BY REGION, 2019-2026 (USD MILLION)
TABLE 37 ONCOLOGY TESTING MARKET, BY TYPE, 2019-2026 (USD MILLION)
8.3.1 BREAST CANCER
8.3.1.1 The increasing prevalence of breast cancer is a key driver for market growth
TABLE 38 ONCOLOGY TESTING MARKET FOR BREAST CANCER, BY REGION, 2019-2026 (USD MILLION)
8.3.2 COLORECTAL CANCER
8.3.2.1 The rising focus on the development of companion diagnostic assays drives the market growth
TABLE 39 ONCOLOGY TESTING MARKET FOR COLORECTAL CANCER, BY REGION, 2019-2026 (USD MILLION)
8.3.3 LUNG CANCER
8.3.3.1 Increasing research for lung cancer biomarkers to drive the market growth
TABLE 40 ONCOLOGY TESTING MARKET FOR LUNG CANCER, BY REGION, 2019-2026 (USD MILLION)
8.3.4 PROSTATE CANCER
8.3.4.1 Advancements in genomic technologies for the development of new biomarkers drive the market growth
TABLE 41 ONCOLOGY TESTING MARKET FOR PROSTATE CANCER, BY REGION, 2019-2026 (USD MILLION)
8.3.5 OTHER CANCERS
TABLE 42 OTHER CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2026 (USD MILLION)
8.4 GENETIC TESTS
8.4.1 GENETIC TESTING ENABLES THE DIAGNOSIS OF VARIOUS DISEASES
TABLE 43 GENETIC TESTS MARKET, BY REGION, 2019-2026 (USD MILLION)
8.5 OTHER APPLICATIONS
TABLE 44 OTHER APPLICATIONS MARKET, BY REGION, 2019-2026 (USD MILLION)

9 MOLECULAR DIAGNOSTICS MARKET, BY END USER (Page No. - 112)
9.1 INTRODUCTION
TABLE 45 MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2019-2026 (USD MILLION)
9.2 DIAGNOSTIC LABORATORIES
9.2.1 INCREASING OUTSOURCING OF ACTIVITIES TO DIAGNOSTIC LABORATORIES FOR REDUCED COSTS DRIVES MARKET GROWTH
TABLE 46 MOLECULAR DIAGNOSTICS MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2019-2026 (USD MILLION)
9.3 HOSPITALS AND CLINICS
9.3.1 THE INCREASING NUMBER OF HOSPITALS WORLDWIDE IS A MAJOR FACTOR DRIVING MARKET GROWTH
TABLE 47 MOLECULAR DIAGNOSTICS MARKET FOR HOSPITALS AND CLINICS, BY REGION, 2019-2026 (USD MILLION)
9.4 OTHER END USERS
TABLE 48 MOLECULAR DIAGNOSTICS MARKET FOR OTHER END USERS, BY REGION, 2019-2026 (USD MILLION)

10 MOLECULAR DIAGNOSTICS MARKET, BY REGION (Page No. - 116)
10.1 INTRODUCTION
TABLE 49 MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2019-2026 (USD MILLION)
10.2 NORTH AMERICA
FIGURE 25 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET SNAPSHOT
TABLE 50 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 51 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION)
TABLE 52 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
TABLE 53 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
TABLE 54 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2019-2026 (USD MILLION)
10.2.1 US
10.2.1.1 The increasing prevalence of infectious diseases and cancer is a key factor expected to drive market growth in the US
TABLE 55 US: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION)
TABLE 56 US: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
TABLE 57 US: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
TABLE 58 US: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2019-2026 (USD MILLION)
10.2.2 CANADA
10.2.2.1 The availability of funding for genomics research in Canada drives the market growth
TABLE 59 CANADA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION)
TABLE 60 CANADA: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
TABLE 61 CANADA: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
TABLE 62 CANADA: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2019-2026 (USD MILLION)
10.3 EUROPE
TABLE 63 EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 64 EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION)
TABLE 65 EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
TABLE 66 EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
TABLE 67 EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2019-2026 (USD MILLION)
10.3.1 GERMANY
10.3.1.1 Increasing healthcare expenditure to drive the market growth in Germany
TABLE 68 GERMANY: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION)
TABLE 69 GERMANY: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
TABLE 70 GERMANY: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
TABLE 71 GERMANY: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2019-2026 (USD MILLION)
10.3.2 ITALY
10.3.2.1 Adoption of advanced diagnostic technologies to drive market growth in Italy
TABLE 72 ITALY: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION)
TABLE 73 ITALY: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
TABLE 74 ITALY: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
TABLE 75 ITALY: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2019-2026 (USD MILLION)
10.3.3 FRANCE
10.3.3.1 Rising R&D expenditure in France to drive the market growth
TABLE 76 FRANCE: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION)
TABLE 77 FRANCE: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
TABLE 78 FRANCE: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
TABLE 79 FRANCE: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2019-2026 (USD MILLION)
10.3.4 RUSSIA
10.3.4.1 Increasing access to quality healthcare will support market growth in Russia
TABLE 80 RUSSIA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION)
TABLE 81 RUSSIA: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
TABLE 82 RUSSIA: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
TABLE 83 RUSSIA: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2019-2026 (USD MILLION)
10.3.5 SPAIN
10.3.5.1 The increasing demand for genetic testing is expected to drive market growth in Spain
TABLE 84 SPAIN: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION)
TABLE 85 SPAIN: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY 2019-2026 (USD MILLION)
TABLE 86 SPAIN: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
TABLE 87 SPAIN: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2019-2026 (USD MILLION)
10.3.6 UK
10.3.6.1 The increasing number of accredited diagnostic laboratories propels market growth for molecular diagnostics in the UK
TABLE 88 UK: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION)
TABLE 89 UK: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
TABLE 90 UK: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
TABLE 91 UK: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2019-2026 (USD MILLION)
10.3.7 REST OF EUROPE
TABLE 92 ROE: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION)
TABLE 93 ROE: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
TABLE 94 ROE: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
TABLE 95 ROE: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2019-2026 (USD MILLION)
10.4 ASIA PACIFIC
FIGURE 26 APAC: MOLECULAR DIAGNOSTICS MARKET SNAPSHOT
TABLE 96 APAC: MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 97 APAC: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION)
TABLE 98 APAC: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
TABLE 99 APAC: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
TABLE 100 APAC: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2019-2026 (USD MILLION)
10.4.1 CHINA
10.4.1.1 Growing public access to modern healthcare and the outbreak of COVID-19 to drive market growth
TABLE 101 CHINA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION)
TABLE 102 CHINA: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
TABLE 103 CHINA: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
TABLE 104 CHINA: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2019-2026 (USD MILLION)
10.4.2 JAPAN
10.4.2.1 Universal healthcare reimbursement policy to drive market growth in Japan
TABLE 105 JAPAN: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION)
TABLE 106 JAPAN: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
TABLE 107 JAPAN: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
TABLE 108 JAPAN: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2019-2026 (USD MILLION)
10.4.3 INDIA
10.4.3.1 Increasing private & public investments in the country’s healthcare system will drive market growth
TABLE 109 INDIA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION)
TABLE 110 INDIA: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
TABLE 111 INDIA: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
TABLE 112 INDIA: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2019-2026 (USD MILLION)
10.4.4 AUSTRALIA
10.4.4.1 The prevalence of infectious diseases in Australia is a key driver for market growth
TABLE 113 AUSTRALIA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION)
TABLE 114 AUSTRALIA: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
TABLE 115 AUSTRALIA: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
TABLE 116 AUSTRALIA: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2019-2026 (USD MILLION)
10.4.5 REST OF ASIA PACIFIC (ROAPAC)
TABLE 117 ROAPAC: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION)
TABLE 118 ROAPAC: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
TABLE 119 ROAPAC: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
TABLE 120 ROAPAC: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2019-2026 (USD MILLION)
10.5 LATIN AMERICA
TABLE 121 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 122 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION)
TABLE 123 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
TABLE 124 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
TABLE 125 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2019-2026 (USD MILLION)
10.5.1 BRAZIL
10.5.1.1 Improving healthcare infrastructure in Brazil to drive the growth of the molecular diagnostics market
TABLE 126 BRAZIL: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION)
TABLE 127 BRAZIL: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
TABLE 128 BRAZIL: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
TABLE 129 BRAZIL: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2019-2026 (USD MILLION)
10.5.2 MEXICO
10.5.2.1 The improving accessibility and affordability of healthcare services to drive market growth for molecular diagnostics
TABLE 130 MEXICO: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION)
TABLE 131 MEXICO: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
TABLE 132 MEXICO: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
TABLE 133 MEXICO: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2019-2026 (USD MILLION)
10.5.3 REST OF LATIN AMERICA
TABLE 134 ROLATAM: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION)
TABLE 135 ROLATAM: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
TABLE 136 ROLATAM: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
TABLE 137 ROLATAM: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2019-2026 (USD MILLION)
10.6 MIDDLE EAST AND AFRICA
TABLE 138 MEA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION)
TABLE 139 MEA: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
TABLE 140 MEA: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
TABLE 141 MEA: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2019-2026 (USD MILLION)

11 COMPETITIVE LANDSCAPE (Page No. - 163)
11.1 OVERVIEW
11.2 KEY PLAYER STRATEGIES
11.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS
11.4 MARKET SHARE ANALYSIS
FIGURE 28 MOLECULAR DIAGNOSTICS MARKET SHARE, BY KEY PLAYERS (2020)
11.4.1 MOLECULAR DIAGNOSTICS MARKET SHARE ANALYSIS, BY TECHNOLOGY
11.4.1.1 Polymerase Chain Reaction (PCR)
FIGURE 29 GLOBAL MOLECULAR DIAGNOSTICS MARKET FOR PCR, MARKET SHARE ANALYSIS, BY KEY PLAYER (2020)
11.4.1.2 DNA Sequencing and NGS
FIGURE 30 GLOBAL MOLECULAR DIAGNOSTICS MARKET FOR DNA SEQUENCING AND NGS, MARKET SHARE ANALYSIS, BY KEY PLAYER (2020)
11.4.1.3 Isothermal Nucleic Acid Amplification Technology (INAAT)
TABLE 142 GLOBAL MOLECULAR DIAGNOSTICS MARKET FOR INAAT, BY KEY PLAYERS, 2020
11.4.1.4 In Situ Hybridization (ISH)
TABLE 143 GLOBAL MOLECULAR DIAGNOSTICS MARKET FOR ISH, BY KEY PLAYERS, 2020
11.4.2 MOLECULAR DIAGNOSTICS MARKET SHARE ANALYSIS, BY APPLICATION
11.4.2.1 Infectious Disease Applications
TABLE 144 GLOBAL INFECTIOUS DISEASE DIAGNOSTICS MARKET RANKING, BY KEY PLAYERS, 2020
11.5 COMPETITIVE LEADERSHIP MAPPING
11.5.1 STARS
11.5.2 EMERGING LEADERS
11.5.3 PERVASIVE PLAYERS
11.5.4 PARTICIPANTS
FIGURE 31 MOLECULAR DIAGNOSTICS MARKET: COMPETITIVE LEADERSHIP MAPPING, 2019
11.6 COMPETITIVE LEADERSHIP MAPPING FOR START-UPS/ SME (2020)
11.6.1 PROGRESSIVE COMPANIES
11.6.2 STARTING BLOCKS
11.6.3 RESPONSIVE COMPANIES
11.6.4 DYNAMIC COMPANIES
FIGURE 32 MOLECULAR DIAGNOSTICS MARKET: COMPETITIVE LEADERSHIP MAPPING FOR START-UPS/ SME, 2019
11.7 PRODUCT AND GEOGRAPHICAL FOOTPRINT ANALYSIS OF TOP PLAYERS
FIGURE 33 PRODUCT AND GEOGRAPHICAL FOOTPRINT ANALYSIS OF TOP PLAYERS IN THE MOLECULAR DIAGNOSTICS MARKET
11.8 COMPETITIVE SCENARIO
FIGURE 34 MARKET EVALUATION MATRIX, 2018-2020
11.8.1 MOLECULAR DIAGNOSTICS: PRODUCT LAUNCHES AND REGULATORY APPROVALS (JANUARY 2018 - MARCH 2021)
TABLE 145 KEY PRODUCT LAUNCHES AND REGULATORY APPROVALS
11.8.2 MOLECULAR DIAGNOSTICS: DEALS (JANUARY 2018 - MARCH 2021)
TABLE 146 KEY DEALS
11.8.3 MOLECULAR DIAGNOSTICS: OTHER DEVELOPMENTS (JANUARY 2018 - MARCH 2021)
TABLE 147 OTHER KEY DEVELOPMENTS

12 COMPANY PROFILES (Page No. - 174)
12.1 KEY PLAYERS
(Business overview, Products offered, Recent developments, SWOT analysis, Right to Win)*
12.1.1 F. HOFFMANN-LA ROCHE LTD.
TABLE 148 F. HOFFMANN-LA ROCHE LTD.: BUSINESS OVERVIEW
FIGURE 35 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2020)
12.1.2 HOLOGIC, INC.
TABLE 149 HOLOGIC, INC.: BUSINESS OVERVIEW
FIGURE 36 HOLOGIC, INC.: COMPANY SNAPSHOT (2020)
12.1.3 BIOMÉRIEUX SA
TABLE 150 BIOMÉRIEUX SA: BUSINESS OVERVIEW
FIGURE 37 BIOMÉRIEUX SA: COMPANY SNAPSHOT (2020)
12.1.4 ABBOTT LABORATORIES
TABLE 151 ABBOTT LABORATORIES: BUSINESS OVERVIEW
FIGURE 38 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2020)
12.1.5 QIAGEN
TABLE 152 QIAGEN: BUSINESS OVERVIEW
FIGURE 39 QIAGEN N.V.: COMPANY SNAPSHOT (2020)
12.1.6 THERMO FISHER SCIENTIFIC INC.
TABLE 153 THERMO FISHER SCIENTIFIC INC.: BUSINESS OVERVIEW
FIGURE 40 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2020)
12.1.7 ILLUMINA, INC.
TABLE 154 ILLUMINA, INC.: BUSINESS OVERVIEW
FIGURE 41 ILLUMINA, INC.: COMPANY SNAPSHOT (2020)
12.1.8 MYRIAD GENETICS INC.
TABLE 155 MYRIAD GENETICS INC.: BUSINESS OVERVIEW
FIGURE 42 MYRIAD GENETICS INC.: COMPANY SNAPSHOT (2019)
12.1.9 SIEMENS HEALTHINEERS AG
TABLE 156 SIEMENS HEALTHINEERS AG: BUSINESS OVERVIEW
FIGURE 43 SIEMENS HEALTHINEERS: COMPANY SNAPSHOT (2020)
12.1.10 DANAHER CORPORATION
TABLE 157 DANAHER CORPORATION: BUSINESS OVERVIEW
FIGURE 44 DANAHER CORPORATION: COMPANY SNAPSHOT (2019)
12.1.11 GRIFOLS S.A.
TABLE 158 GRIFOLS S.A.: BUSINESS OVERVIEW
FIGURE 45 GRIFOLS S.A: COMPANY SNAPSHOT (2020)
12.1.12 AGILENT TECHNOLOGIES INC.
TABLE 159 AGILENT TECHNOLOGIES INC.: BUSINESS OVERVIEW
FIGURE 46 AGILENT TECHNOLOGIES INC.: COMPANY SNAPSHOT (2020)
12.1.13 BECTON, DICKINSON AND COMPANY
TABLE 160 BECTON, DICKINSON AND COMPANY: BUSINESS OVERVIEW
FIGURE 47 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2020)
12.1.14 DIASORIN S.P.A
TABLE 161 DIASORIN S.P.A: BUSINESS OVERVIEW
FIGURE 48 DIASORIN S.P.A: COMPANY SNAPSHOT (2019)
12.2 START UP/ SME PLAYERS
12.2.1 QUIDEL CORPORATION
TABLE 162 QUIDEL CORPORATION: BUSINESS OVERVIEW
FIGURE 49 QUIDEL CORPORATION: COMPANY SNAPSHOT (2019)
12.2.2 GENETIC SIGNATURES
TABLE 163 GENETIC SIGNATURES: BUSINESS OVERVIEW
FIGURE 50 GENETIC SIGNATURES: COMPANY SNAPSHOT (2020)
12.2.3 MDX HEALTH
TABLE 164 MDX HEALTH: BUSINESS OVERVIEW
FIGURE 51 MDX HEALTH: COMPANY SNAPSHOT (2019)
12.2.4 EXACT SCIENCES
TABLE 165 EXACT SCIENCES: BUSINESS OVERVIEW
FIGURE 52 EXACT SCIENCES: COMPANY SNAPSHOT (2019)
12.2.5 BIOCARTIS NV
TABLE 166 BIOCARTIS NV: BUSINESS OVERVIEW
FIGURE 53 BIOCARTIS NV: COMPANY SNAPSHOT (2019)
12.2.6 TBG DIAGNOSTICS LTD.
TABLE 167 TBG DIAGNOSTICS LTD.: BUSINESS OVERVIEW
FIGURE 54 TBG DIAGNOSTICS LTD.: COMPANY SNAPSHOT (2019)
12.2.7 GENMARK DIAGNOSTICS INC.
TABLE 168 GENMARK DIAGNOSTICS INC.: BUSINESS OVERVIEW
FIGURE 55 GENMARK DIAGNOSTICS INC.: COMPANY SNAPSHOT (2019)
12.2.8 LUMINEX CORPORATION
TABLE 169 LUMINEX CORPORATION: BUSINESS OVERVIEW
FIGURE 56 LUMINEX CORPORATION: COMPANY SNAPSHOT (2019)
12.2.9 HTG MOLECULAR DIAGNOSTICS
TABLE 170 HTG MOLECULAR DIAGNOSTICS: BUSINESS OVERVIEW
FIGURE 57 HTG MOLECULAR DIAGNOSTICS: COMPANY SNAPSHOT (2019)
12.2.10 VELA DIAGNOSTICS
TABLE 171 VELA DIAGNOSTICS: BUSINESS OVERVIEW
12.2.11 AMOY DIAGNOSTICS CO. LTD.
TABLE 172 AMOY DIAGNOSTICS CO. LTD.: BUSINESS OVERVIEW
12.2.12 MOLBIO DIAGNOSTICS PVT. LTD.
TABLE 173 MOLBIO DIAGNOSTICS PVT. LTD.: BUSINESS OVERVIEW
12.2.13 ELITECHGROUP
TABLE 174 ELITECHGROUP: BUSINESS OVERVIEW
12.2.14 SAVYON DIAGNOSTICS LTD.
TABLE 175 SAVYON DIAGNOSTICS LTD.: BUSINESS OVERVIEW
12.2.15 ABACUS DIAGNOSTICA OY
TABLE 176 ABACUS DIAGNOSTICS OY: BUSINESS OVERVIEW
12.2.16 GENEOMBIO TECHNOLOGIES PVT LTD.
TABLE 177 GENEOMBIO TECHNOLOGIES PVT. LTD.: BUSINESS OVERVIEW
*Business overview, Products offered, Recent developments, SWOT analysis, Right to Win might not be captured in case of unlisted companies.

13 APPENDIX (Page No. - 265)
13.1 INSIGHTS FROM INDUSTRY EXPERTS
13.2 DISCUSSION GUIDE
13.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
13.4 AVAILABLE CUSTOMIZATIONS
13.5 RELATED REPORTS
13.6 AUTHOR DETAILS